Bicycle finally falls
The company admits defeat with zelenectide.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
